Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.65 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HK1 | P19367 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GALK1 | P51570 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11554130 | 0.81 | BRD4 (0.44) | BRD4CREBBPSMN1; SMN2GAAKDM4E | |
| SCHEMBL677636 | 0.78 | BRD4 (1.00) | BRD4CREBBPNPC1MAPTAHR | |
| SCHEMBL10061695 | 0.77 | BRD4 (0.65) | BRD4CREBBPNPC1KDM4EMEN1 | |
| SCHEMBL2629391 | 0.77 | EPHX2 (0.54) | BRD4CREBBPSMN1; SMN2MEN1MAPT | |
| SCHEMBL904990 | 0.77 | BRD4 (0.65) | BRD4CREBBPNPC1KDM4EMEN1 | |
| SCHEMBL18034998 | 0.77 | — | — | |
| SCHEMBL23066488 | 0.75 | SMN1; SMN2 (0.40) | BRD4CREBBPSMN1; SMN2GAAMEN1 | |
| SCHEMBL2628443 | 0.75 | TSPO (0.58) | — | |
| SCHEMBL232686 | 0.72 | GAA (0.54) | BRD4CREBBPSMN1; SMN2GAAMEN1 | |
| SCHEMBL16300951 | 0.71 | TSPO (0.48) | BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569380-B2 | Oligomer-tricyclic conjugates | NEKTAR THERAPEUTICS (US) | 2013-10-29 | — | — | US | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | BATT ANDRZEJ ROMAN (GB) | 2012-04-26 | — | — | US | disclosed |
| WO-2011091050-A1 | OLIGOMER-TRICYCLIC CONJUGATES | NEKTAR THERAPEUTICS (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100298296-A1 | Oligomer-Tricyclic Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-25 | — | — | US | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298296-A1 | Oligomer-Tricyclic Conjugates | ABCG2, SLCO1B3, SLC43A1 | BRD4 2185/4885CREBBP 4884/4885SMN1; SMN2 2837/4885 |
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | AVPR1A, AVPR2, AVPR1B | BRD4 3900/4885CREBBP 4676/4885SMN1; SMN2 4623/4885 |
| US-20090029965-A1 | Vasopressin V1a Antagonists | AVPR1A, AVPR2, AVPR1B | BRD4 3900/4885CREBBP 4676/4885SMN1; SMN2 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.